Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Ca...
May 22 2018 - 5:00AM
Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of
stapled peptide therapeutics for cancers and other diseases, today
announced the publication of nonclinical results in Nature
Communications demonstrating the anti-cancer potential of
ALRN-6924 in models of T-cell lymphoma (TCL). ALRN-6924 is designed
to reactivate p53-mediated tumor suppression by targeting the two
primary p53 suppressor proteins, MDM2 and MDMX. ALRN-6924 is being
evaluated in Phase 1 and Phase 2 clinical trials in patients with
peripheral T-cell lymphoma (PTCL) and acute myeloid leukemia (AML)
and myelodysplastic syndrome (MDS).
As reported in the study, ALRN-6924 showed potent in vitro
activity and superior in vivo activity across eight different
patient-derived xenograft models, compared to the standard-of-care
agent. Separately, it was noted in the publication that ALRN-6924
induced a complete remission in a patient with TP53-wild-type
angioimmunoblastic T-cell lymphoma, demonstrating the potential for
rapid translation of discoveries from preclinical models.
“These data independently confirm previous preclinical and
clinical results that the stapled peptide ALRN-6924 possesses
anti-cancer activity based on a novel mechanism of action—the dual
inhibition of MDMX and MDM2, instead of the inhibition of MDM2
alone. In addition, these data further demonstrate that stapled
peptides represent a new treatment modality with unique properties
that enable the targeting of previously ‘undruggable’ targets,”
said Manuel Aivado, MD, PhD, Chief Medical and Scientific Officer
of Aileron.
“We were very gratified by these results,” said David Weinstock,
MD, Principal Investigator and Associate Professor of Medicine at
Dana-Farber Cancer Institute and Harvard Medical School. “The
xenograft models we created and tested provide significant insight
into the activity of a drug like ALRN-6924 and how well it will
work in patients. We’re excited to see this drug move forward
in clinical trials and hope to better understand the best way to
use it as either a single agent or in combinations.”
The study in Nature Communications is titled,
“Targetable Vulnerabilities in T- and NK-cell Lymphomas Identified
Through Preclinical Models.”
About ALRN-6924ALRN-6924 is a first-in-class
product candidate designed to reactivate wild type p53 tumor
suppression by disrupting the interactions between the two primary
p53 suppressor proteins, MDMX and MDM2. Aileron believes ALRN-6924
is the first and only product candidate in clinical development
that can equipotently bind to and disrupt the interaction of MDMX
and MDM2 with p53. Based on preclinical data and preliminary
evidence of safety and anti-tumor activity in its ongoing clinical
trials, there may be a significant opportunity to develop ALRN-6924
as a monotherapy or combination therapy for a wide variety of solid
and liquid tumors. ALRN-6924 is currently being evaluated in
multiple clinical trials for the treatment of acute myeloid
leukemia (AML), advanced myelodysplastic syndrome (MDS) and
peripheral T-cell lymphoma (PTCL). For information about its
clinical trials, please visit www.clinicaltrials.gov.
About AileronAileron is a clinical-stage
biopharmaceutical company advancing stapled peptides, a novel class
of therapeutics for cancers and other diseases. Stapled peptides
are chemically stabilized alpha-helical peptides that are modified
to improve their stability and cell penetrability while maintaining
high affinity for large protein surfaces. Our goal is to use our
proprietary stapled peptide drug platform to create first-in-class
therapeutics, like ALRN-6924, that may be able to address
historically undruggable targets and complex mechanisms that
underlie many diseases with high unmet medical need. Our platform
enables us to chemically stabilize and improve the performance and
activity of a broad range of alpha-helical peptides that we believe
can potentially activate and inhibit key cellular functions that
are otherwise difficult to target with existing drug technologies,
including small molecules and monoclonal antibodies. For more
information, visit www.aileronrx.com.
Forward-Looking Statements Statements in
this press release about Aileron's future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements about the company’s cash
forecast, the sufficiency of the Company’s cash resources and the
timing of clinical trial enrollments and data. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “would” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including whether Aileron’s cash resources will be
sufficient to fund its continuing operations for the periods and/or
trials anticipated; whether results obtained in preclinical or
nonclinical studies and clinical trials such as the nonclinical
data presented in this release will be indicative of results
obtained in future clinical trials; whether Aileron’s product
candidates will advance through the clinical trial process on a
timely basis, or at all; whether the results of such trials will
warrant submission for approval from the United States Food
and Drug Administration or equivalent foreign regulatory
agencies; whether Aileron's product candidates will
receive approval from regulatory agencies on a timely basis or at
all; whether, if product candidates obtain approval, they will be
successfully distributed and marketed; and other factors discussed
in the "Risk Factors" section of Aileron's quarterly
report on Form 10-Q for the period ended March 31, 2018, filed
on May 9, 2018, and risks described in other filings that
Aileron may make with the Securities and Exchange Commission.
Any forward-looking statements contained in this press release
speak only as of the date hereof,
and Aileron specifically disclaims any obligation to
update any forward-looking statement, whether because of new
information, future events or otherwise.
Source: Aileron Therapeutics
Investors:
Aileron Therapeutics
Don Dougherty, CFO
617-995-0900
ddougherty@aileronrx.com
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com
Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Jul 2023 to Jul 2024